Pneumologie

Real-life omalizumab exposure and discontinuation

Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of pediatric and adult asthmatics

INTRODUCTION

This real-life study aimed to assess omalizumab treatment patterns in adult and pediatric asthma patients, and to describe asthma control and healthcare resource use (HCRU) at omalizumab initiation and discontinuation.

The French Healthcare Database System (SNDS) was used to identify asthma patients aged ≥6 years who initiated omalizumab for at least 16 weeks from 2009 to 2019. We examined omalizumab treatment patterns using dispensation records..

find the whole article here ==>doi: 10.1183/13993003.03130-2021

Authors
Humbert M, Bourdin A, Taillé C, Kamar D, Thonnelier C, Lajoinie A, Rigault A, Deschildre A, Molimard M.

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Methodological challenges in the evaluation of prescription support software: Lessons from PMCF alert validation
Actualités RCTS - Publications - Autres - Facultatif

Methodological challenges in the evaluation of prescription support software: Lessons from PMCF alert validation

Machine Learning for Missing Data Imputation in Healthcare Research: A Systematic Review of Methods and Applications
Actualités RCTS - Publications - Autres - Facultatif

Machine Learning for Missing Data Imputation in Healthcare Research: A Systematic Review of Methods and Applications

Impact de l’action d’accompagnement Mycocare sur la prise en charge des patients atteints d’infections pulmonaires aux Mycobactéries Non Tuberculeuses
Actualités RCTS - Publications - Infectieux - Facultatif

Impact de l’action d’accompagnement Mycocare sur la prise en charge des patients atteints d’infections pulmonaires aux Mycobactéries Non Tuberculeuses